Supriya Lifescience share allotment today. How to check application status
1 min read 23 Dec 2021, 07:48 AM ISTSupriya Lifescience IPO had a fresh issue of up to ₹200 crore and an offer for sale of up to ₹500 crore with price range fixed at ₹265-274
PremiumThe finalization of basis of share allotment of Supriya Lifescience IPO is expected to take place today and if allotted, then the credit of shares to demat account of bidders will be done on December 27. The company's shares are expected to list next week on Tuesday, December 28 on the leading stock exchanges NSE and BSE.
The three-day initial public offering (IPO) of Supriya Lifescience Limited was subscribed 71.51 times on the last day of share sale on Monday. The initial share sale received bids for 1,03,89,57,138 shares against 1,45,28,299 shares on offer. The price range for the issue was fixed at ₹265-274 per share.
The registrar for this IPO is Link Intime India Private Ltd, therefore the bidders who applied for the public issue can check their respective application status online on the registrar's website here or on the BSE website here.
Supriya Lifescience's initial share sale had a fresh issue of up to ₹200 crore and an offer for sale of up to ₹500 crore. It had a price range of ₹265-274 per share. The company had raised ₹315 crore from anchor investors ahead of its IPO.
The issue was fully subscribed within a few hours on first day of subscription that opened on December 16 on the back of a strong response from retail investors. The proceeds from the fresh issue will be used for funding capital expenditure requirements, debt repayment, and general corporate purposes.
According to market observers, Supriya Lifescience shares are commanding a premium (GMP) of ₹110 in the grey market. The grey market is an unofficial platform, wherein trading starts after the announcement of IPO price band till the listing of shares.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceutical ingredients, with a focus on research and development. As of October 31, 2021, the company had product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
